A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD
3期
已完成
NCT05138250
| 适应症 | COPD |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Sheffield Teaching Hospitals NHS Foundation Trust |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 31 人 |
|---|
| 干预（药物） | Mepolizumab 100 MG |
|---|
| 开始日期 | 2022年5月8日 |
|---|
| 完成日期 | 2025年5月8日 |
|---|
| 结果公布日 | 2026年5月7日 |
|---|
摘要
The investigators aim to recruit 32 people with COPD who have frequent exacerbations and high eosinophil counts which indicates "asthmatic type" inflammation and treat them for a year with mepolizumab. This is a licenced medication for asthma. Mepolizumab is a monoclonal antibody that acts through interleukin-5 (IL-5) antagonism to reduce blood eosinophil levels and is effective at reducing exacerbations in asthmatics. To determine whether mepolizumab may be an effective treatment in people with COPD and "asthmatic type" inflammation participants will have MRI scans before the treatment, after 12 weeks and after a year to see how the drug affects inflammation. The investigators will also compare our measurements with the number of exacerbations people get (measured by diaries), with measures of their quality of life (using a questionnaire), and with ordinary laboratory breathing tests. The investigators are especially interested to know if the reduction in inflammation early on after 12 weeks is associated with fewer exacerbations and better quality of life over the year.
Change in Percentage Ventilated Defect Percent (VDP)
Baseline to 12 weeks of treatment · % change in VDP
| Treatment Arm (All Participants, Not Randomised) | -0.14 ± 6.5 % change in VDP |
|---|
Change in Pulmonary Inflammation
From Baseline to 12 weeks of treatment · ratio
| Participants Completing Assessment 2 | -0.00009 ratio |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
同一适应症的其他试验
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。